---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000044"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T17:24:07.261972+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech stockholders elect three Class III directors at 2023 annual meeting

## Summary
- Krish S. Krishnan, Kirti Ganorkar, and Christopher Mason elected as Class III directors for three-year terms.
- Ratification of KPMG as independent auditor for FY2023 approved (22,098,460 for, 2,547 against).
- Advisory vote on named executive officer compensation approved (18,759,786 for, 907,235 against).

## SEC filing metadata
- accession: 0001711279-23-000044
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000044/0001711279-23-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000044/krys-20230523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000044
- JSON: https://secwatch.observer/filing/0001711279-23-000044.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000044.txt

## Key facts
- Shareholder Votes
  Krystal Biotech, Inc. shareholders approved Non-Binding, Advisory Vote On Named Executive Officer Compensation at the 2023-05-19 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-19
  source text: Proposal Three: Non-Binding, Advisory Vote On Named Executive Officer Compensation The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2022, as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 18,759,786 907,235 7,389 2,431,170
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000044/0001711279-23-000044-index.htm
- Shareholder Votes
  Krystal Biotech, Inc. shareholders approved Election of Class III Directors at the 2023-05-19 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-19
  source text: Proposal One: Election of Class III Directors The Company’s stockholders elected Krish S. Krishnan, Kirti Ganorkar, and Christopher Mason as members of the Company’s Board of Directors as Class III directors for a three-year term. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Krish S. Krishnan 15,620,498 4,053,912 2,431,170 Kirti Ganorkar 14,761,072 4,913,338 2,431,170 Christopher Mason 15,864,807 3,809,603 2,431,170
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000044/0001711279-23-000044-index.htm
- Shareholder Votes
  Krystal Biotech, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-19 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-19
  source text: Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 22,098,460 2,547 4,573
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000044/0001711279-23-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.